Jason Theodoropoulos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jason Theodoropoulos has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Satu Mustjoki
Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Centre Helsinki, Helsinki, Finland
134 shared publications - Anita Kumari
University of Helsinki 1 Hematology Research Unit Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
133 shared publications - Anna Kreutzman
University of Helsinki 1 Hematology Research Unit Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
133 shared publications - Karita Peltonen
University of Helsinki 1 Hematology Research Unit Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
133 shared publications - Moon Hee Lee
University of Helsinki 1 Hematology Research Unit Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
133 shared publications - Petrus Järvinen
Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
133 shared publications
Latest Publications
- Open Access
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S14 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Differentially expressed genes (DEGs) in pseudobulked treatment vs control in NK cells, B cells and Myeloid population
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S14 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Differentially expressed genes (DEGs) in pseudobulked treatment vs control in NK cells, B cells and Myeloid population
- Open Access
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Patient-derived ex vivo model validation and anti-CD3/CD28/CD2 responses (related to Fig. 4).
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Patient-derived ex vivo model validation and anti-CD3/CD28/CD2 responses (related to Fig. 4).
- Open Access
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Effect size of the cytokines used in Cytokine panel per treatment
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Effect size of the cytokines used in Cytokine panel per treatment
- Open Access
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
The effects of anti–PD-1 (pembrolizumab), VEGFRi (axitinib), and their combination on immune cell functionality in the RCC TME. A, Volcano plot illustrating changes in cytokine secretion in response to anti–PD-1, VEGFRi, or anti–PD-1 + VEGFRi combination. Each point represents a cytokine, and upregulated and statistically significant cytokines are highlighted in dark red, whereas downregulated and statistically significant cytokines are colored in dark blue [−log10(P) > −log10(0.05) or P > 0.05]. B, Heatmap comparing change in immune effector markers expression between control, anti–PD-1, VEGFRi, or anti–PD-1 + VEGFRi combination in CD8+ and CD4+ T cells. C, Volcano plot illustrating changes in gene expression in response to anti–PD-1, VEGFRi, or anti–PD-1 + VEGFRi combination in CD8+ T cells (i) or CD4+ T cells (ii). Each point represents a gene, the upregulated genes are colored dark red, whereas downregulated genes are dark blue. Only significant genes are labeled [adjusted P value < 0.05 and abs(avg_log2FC) > 0.5, and in the case of anti–PD-1 adjusted P value < 0.05 and abs(avg_log2FC) > 0.3]. D, Dot plot of selected immunology-related hallmark pathways, comparing anti–PD-1, VEGFRi, or anti–PD-1 + VEGFRi to control condition. Genes were identified using the FindMarkers method and included if the P value was < 0.05. Circle size represents the logP value, whereas color indicates the percentage of genes in our dataset that are upregulated (+) or downregulated (−). E, Volcano plot illustrating changes in relative cluster size in response to anti–PD-1, VEGFRi, or anti–PD-1 + VEGFRi combination treatments. Each point represents a T cell cluster (CD8+ T cells and CD4+ T cells). Cell populations that are enriched in treatment and statistically significant (adjusted P value < 0.05 and log2FC > 0) are highlighted in dark red, and cell populations that are diminished in treatments and statistically significant (adjusted P value < 0.05 and log2FC < 0) are colored in dark blue. FC, fold change. F, Signature score distributions for terminally exhausted, progenitor exhausted and IFN CD8+ T cell signatures comparing control with anti–PD-1, VEGFRi, anti–PD-1 + VEGFRi, and anti-CD3/CD28/CD2. Statistical significance of differential signature enrichment (P value) between subtypes was determined by two-sided Wilcoxon rank-sum test (ns, P > 0.05; ****, P ≤ 0.0001).
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
The effects of anti–PD-1 (pembrolizumab), VEGFRi (axitinib), and their combination on immune cell functionality in the RCC TME. A, Volcano plot illustrating changes in cytokine secretion in response to anti–PD-1, VEGFRi, or anti–PD-1 + VEGFRi combination. Each point represents a cytokine, and upregulated and statistically significant cytokines are highlighted in dark red, whereas downregulated and statistically significant cytokines are colored in dark blue [−log10(P) > −log10(0.05) or P > 0.05]. B, Heatmap comparing change in immune effector markers expression between control, anti–PD-1, VEGFRi, or anti–PD-1 + VEGFRi combination in CD8+ and CD4+ T cells. C, Volcano plot illustrating changes in gene expression in response to anti–PD-1, VEGFRi, or anti–PD-1 + VEGFRi combination in CD8+ T cells (i) or CD4+ T cells (ii). Each point represents a gene, the upregulated genes are colored dark red, whereas downregulated genes are dark blue. Only significant genes are labeled [adjusted P value < 0.05 and abs(avg_log2FC) > 0.5, and in the case of anti–PD-1 adjusted P value < 0.05 and abs(avg_log2FC) > 0.3]. D, Dot plot of selected immunology-related hallmark pathways, comparing anti–PD-1, VEGFRi, or anti–PD-1 + VEGFRi to control condition. Genes were identified using the FindMarkers method and included if the P value was < 0.05. Circle size represents the logP value, whereas color indicates the percentage of genes in our dataset that are upregulated (+) or downregulated (−). E, Volcano plot illustrating changes in relative cluster size in response to anti–PD-1, VEGFRi, or anti–PD-1 + VEGFRi combination treatments. Each point represents a T cell cluster (CD8+ T cells and CD4+ T cells). Cell populations that are enriched in treatment and statistically significant (adjusted P value < 0.05 and log2FC > 0) are highlighted in dark red, and cell populations that are diminished in treatments and statistically significant (adjusted P value < 0.05 and log2FC < 0) are colored in dark blue. FC, fold change. F, Signature score distributions for terminally exhausted, progenitor exhausted and IFN CD8+ T cell signatures comparing control with anti–PD-1, VEGFRi, anti–PD-1 + VEGFRi, and anti-CD3/CD28/CD2. Statistical significance of differential signature enrichment (P value) between subtypes was determined by two-sided Wilcoxon rank-sum test (ns, P > 0.05; ****, P ≤ 0.0001).
- Open Access
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S16 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Secreted Signaling interactions according to Cell-chat
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S16 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Secreted Signaling interactions according to Cell-chat
- Open Access
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Curated gene signatures used to characterize CD4+ T cells (Based on Bi et.al.)
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Curated gene signatures used to characterize CD4+ T cells (Based on Bi et.al.)
- Open Access
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Differentially expressed genes (DEGs) in pseudobulked treatment vs control in CD8+ cells
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Differentially expressed genes (DEGs) in pseudobulked treatment vs control in CD8+ cells
- Open Access
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S12 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Differentially expressed genes (DEGs) in pseudobulked treatment vs control in CD4+ cells
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S12 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Differentially expressed genes (DEGs) in pseudobulked treatment vs control in CD4+ cells
- Open Access
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S15 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Enriched pathways in differentially expressed genes (DEGs) in treatment vs control in B, myloid and NK cells according to Metascape
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S15 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Enriched pathways in differentially expressed genes (DEGs) in treatment vs control in B, myloid and NK cells according to Metascape
- Open Access
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Top 50 differentially expressed genes (DEGs) for 14 CD8+ T cell clusters
- 26 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models
Top 50 differentially expressed genes (DEGs) for 14 CD8+ T cell clusters